scholarly journals Anti-Angiogenesis, Gene Therapy, and Immunotherapy in Malignant Gliomas

10.5772/58320 ◽  
2014 ◽  
Author(s):  
Paula Province ◽  
Alexis Bashinski Shaefer ◽  
Benjamin McCullough ◽  
Hassan M. Fathallah-Shaykh
Keyword(s):  
Gene Therapy ◽  
Malignant Gliomas

Human Gene Therapy for Malignant Gliomas

2007 ◽  
pp. 119-123
Author(s):  
Toshihiko Wakabayashi ◽  
Jun Yoshida ◽  
Masaaki Mizuno ◽  
Masazumi Fujii ◽  
Yasukazu Kajita ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Human Gene ◽  
Malignant Gliomas ◽  
Human Gene Therapy

Gene Therapy of Rat Malignant Gliomas Using Neural Stem Cells Expressing IL-12

2004 ◽  
Vol 23 (6) ◽  
pp. 381-389 ◽  
Author(s):  
Shu-Yuan Yang ◽  
Hui Liu ◽  
Jian-Ning Zhang
Keyword(s):  
Stem Cells ◽  
Gene Therapy ◽  
Neural Stem Cells ◽  
Malignant Gliomas

scholarly journals Sufasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas

2007 ◽  
Author(s):  
Pierre Robe ◽  
Minh-Tuan Nguyen-Khac ◽  
Frederic Lambert ◽  
Chantal Lechanteur ◽  
Olivier Jolois ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Bystander Effect ◽  
Malignant Gliomas

Application of the Apoptotic Gene to Gene Therapy of Malignant Gliomas

Brain Tumor ◽  
1996 ◽  
pp. 397-407
Author(s):  
Akio Asai ◽  
Chifumi Kitanaka ◽  
Akinori Sugiyama ◽  
Kazuhiko Mishima ◽  
Yoshiyuki Kuchino
Keyword(s):  
Gene Therapy ◽  
Malignant Gliomas ◽  
Apoptotic Gene

Current Non-Viral Gene Therapy Strategies for the Treatment of Glioblastoma

2021 ◽  
Vol 28 ◽  
Author(s):  
Antonela Sofía Asad ◽  
Alejandro Javier Nicola Candia ◽  
Nazareno González ◽  
Camila Florencia Zuccato ◽  
Adriana Seilicovich ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Blood Brain Barrier ◽  
Viral Vectors ◽  
Malignant Gliomas ◽  
Brain Parenchyma ◽  
Brain Barrier ◽  
Viral Gene ◽  
Normal Brain ◽  
Blood Brain ◽  
Transgene Delivery

Background: Glioblastoma constitutes the most frequent and aggressive primary malignant brain tumor in adults. Despite the advances in its treatment, its prognosis remains very poor. Gene therapy has been proposed as a complementary treatment, since it may overcome the problem of the blood-brain barrier for systemic therapies, allowing to target tumor cells and their tumor microenvironment locally, without affecting the normal brain parenchyma. In comparison with viral vectors, non-viral vectors became an attractive tool due to their reduced potential of biosafety risks, lower cost, higher availability and easy storage. Objective: In this article, we aimed to outline the current preclinical and clinical developments of non-viral delivery systems for therapeutic transgene delivery in malignant gliomas. Conclusion: Non-viral vectors are efficient tools for gene delivery since they exhibit reduced non-specific cytotoxicity and can go through several modifications in order to achieve high tumor tropism and the ability to cross the blood-brain barrier to access the tumor mass. However, further evaluations in preclinical models and clinical trials are required in order to translate it into the neuro-oncology clinic.

scholarly journals In vitro and in vivo effects of retrovirus-mediated transfer of the connexin 43 gene in malignant gliomas: consequences for HSVtk/GCV anticancer gene therapy

Gene Therapy ◽  
1998 ◽  
Vol 5 (9) ◽  
pp. 1221-1226 ◽  
Author(s):  
N Cirenei ◽  
BM Colombo ◽  
M Mesnil ◽  
S Benedetti ◽  
H Yamasaki ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Connexin 43 ◽  
Malignant Gliomas ◽  
In Vivo Effects

Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor

2000 ◽  
Vol 92 (6) ◽  
pp. 1002-1008 ◽  
Author(s):  
Katsuyuki Asaoka ◽  
Mitsuhiro Tada ◽  
Yutaka Sawamura ◽  
Jun Ikeda ◽  
Hiroshi Abe
Keyword(s):  
Gene Therapy ◽  
Cell Lines ◽  
Malignant Gliomas ◽  
Transduction Efficiency ◽  
Wild Type ◽  
Content Type ◽  
Expression Levels ◽  
Coxsackievirus And Adenovirus Receptor ◽  
Adenovirus Receptor ◽  
Fine Print

Object. Recombinant adenovirus is used as a competent vector in a wide spectrum of cancer gene therapies because of its high efficiency in gene delivery. To study the feasibility of gene therapy in malignant gliomas, the authors examined the antiproliferative effect of the adenovirally transduced wild-type p53 tumor suppressor gene by using 15 different high-grade glioma cell lines.Methods. Although growth suppression in association with a high adenoviral p53 transduction efficiency was seen in five of 15 cell lines, it was not observed in the remaining 10 cell lines. To clarify the underlying mechanism, we examined the expression levels of the Coxsackievirus and adenovirus receptor (CAR), which is the primary receptor for adenovirus, and of the integrins αvβ3 and αvβ5, which promote adenoviral internalization. The expression level of the CAR gene showed a close correlation to adenoviral gene transduction efficiency in the tested cell lines, whereas the expression levels of the integrins did not. The CAR expression was decreased by wild-type p53 transduction in U251MG cells harboring mutant p53 and increased by antisense inhibition of p53 in LN443 cells with endogenous wild-type p53.Conclusions. The results of this study indicate that CAR expression is a critical determinant of transduction efficiencies in adenovirus-based gene therapy for human malignant gliomas.

Sign in / Sign up

Export Citation Format

Share Document